Head to Head Comparison: Bruker (BRKR) versus BioNano Genomics (BNGO)

Bruker (NASDAQ:BRKR) and BioNano Genomics (NASDAQ:BNGO) are both computer and technology companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk.

Analyst Ratings

This is a summary of current ratings for Bruker and BioNano Genomics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bruker 2 4 1 0 1.86
BioNano Genomics 0 0 2 0 3.00

Bruker currently has a consensus price target of $34.71, indicating a potential upside of 13.45%. BioNano Genomics has a consensus price target of $12.00, indicating a potential upside of 84.33%. Given BioNano Genomics’ stronger consensus rating and higher probable upside, analysts plainly believe BioNano Genomics is more favorable than Bruker.


Bruker pays an annual dividend of $0.16 per share and has a dividend yield of 0.5%. BioNano Genomics does not pay a dividend. Bruker pays out 13.2% of its earnings in the form of a dividend.

Institutional & Insider Ownership

64.9% of Bruker shares are owned by institutional investors. Comparatively, 80.3% of BioNano Genomics shares are owned by institutional investors. 35.2% of Bruker shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


This table compares Bruker and BioNano Genomics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bruker 5.24% 27.46% 11.52%
BioNano Genomics N/A N/A N/A

Earnings and Valuation

This table compares Bruker and BioNano Genomics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bruker $1.77 billion 2.71 $78.60 million $1.21 25.29
BioNano Genomics $9.50 million 6.87 -$23.36 million N/A N/A

Bruker has higher revenue and earnings than BioNano Genomics.


Bruker beats BioNano Genomics on 7 of the 13 factors compared between the two stocks.

About Bruker

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, and defect-detection equipment for semiconductor process control, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments and spark optical emission spectroscopy systems. In addition, it offers superconducting and non-superconducting materials and devices. The company serves pharmaceutical, biotechnology and diagnostics, chemical, food and beverage, clinical, polymer, nanotechnology, semiconductor, and industrial companies; nonprofit laboratories; contract research organizations, academic institutions, medical schools, nonprofit or for-profit forensics, agriculture, food and beverage safety, environmental and clinical microbiology laboratories, hospitals, and government departments and agencies; and raw material manufacturers, and other businesses involved in materials analysis. It markets its products through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was founded in 1991 and is headquartered in Billerica, Massachusetts.

About BioNano Genomics

BioNano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. BioNano Genomics, Inc. also provides Bionano prep kits and labeling kits that provide the critical reagents and protocols needed to extract and label high molecular weight, or HMW, DNA for use with the Saphyr system; and data solutions that includes a suite of hardware and software for experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. The company was formerly known as BioNanomatrix, Inc. and changed its name to BioNano Genomics, Inc. in October 2011. The company was founded in 2003 and is headquartered in San Diego, California.

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply